MyDosageBeta
Scan
Tripeptide (α-MSH fragment)

KPV

C-terminal α-MSH tripeptide with anti-inflammatory action; investigated for IBD and skin inflammation.

Preclinical only · t½ Short · 200–500 mcg/day (anecdotal)

Start with a product

Pick what you have. We'll guide the rest.

Schedule, what to expect, side-effects to watch — built around your exact product.

Scan a productAdd manually
CPreclinical onlyPreclinicalTripeptide (α-MSH fragment)

Also: α-MSH(11-13)

C-terminal α-MSH tripeptide with anti-inflammatory action; investigated for IBD and skin inflammation.

Scientific Consensus Engine

Evidence Intelligence Score™

Heuristic — no indexed evidence yet
3.9/ 10
Overall confidence
Insufficient
Outlook
Emerging
Evidence maturity
  1. Preclinical← current
  2. Pilot human
  3. RCT
  4. Multi-RCT
  5. Meta-analysis

Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.

Eight-dimension breakdown
  1. Human evidence
    Weight of RCT and observational data
    3.8
  2. Safety maturity
    Follow-up depth and adverse-event signal
    3.0
  3. Mechanism confidence
    Pathway specificity and clarity
    6.1
  4. Clinical readiness
    Distance to physician-prescribable use
    2.8
  5. Research momentum
    Recency of indexed clinical evidence
    5.0
  6. Study consistency
    Effect direction across cohorts
    4.4
  7. Long-term data
    Follow-up beyond initial trial windows
    1.8
  8. Translational confidence
    Animal → human signal preservation
    4.3
Strongest supported claim

Mechanistic and preclinical evidence is suggestive; controlled human trials are not yet on the index.

Weakest / unclear

Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.

Major unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Scientific outlook

Outlook: speculative. A grade upgrade requires controlled human evidence, not additional preclinical confirmation.

Reported outcomes · graded
Chronic joint pain
Dgrade
2.5
Mechanism
Inhibits NF-κB and pro-inflammatory cytokine signalling.
Reported uses
Clinical evidence · 2 studies indexed

Tissue & joint repair

1 study

Gut health & inflammation

1 study
Observed research protocols · 2 regimens

Gut health & inflammation

1 regimen
Preclinicalsource ↗

Animal model. No human IBD trials of KPV monotherapy.

Preclinical only.

Tissue & joint repair

1 regimen
Preclinicalsource ↗

Animal/in vitro evidence. KPV is not an approved therapeutic.

Preclinical only.

These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.

Citations
What we don't know yet
  • —Long-term safety beyond reported study durations.
  • —Effect size in populations under-represented in the cited trials.
  • —Interactions with concomitant medications outside listed contraindications.

We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.

Editorial team
Independent · No affiliate revenue
Reviewed quarterly